Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,500.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the sale, the chief financial officer now owns 23,000 shares in the company, valued at $517,500. The trade was a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.74 during trading hours on Wednesday, hitting $20.58. The company had a trading volume of 260,852 shares, compared to its average volume of 270,231. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -10.83 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52 week low of $15.96 and a 52 week high of $30.03. The firm has a 50 day simple moving average of $21.34 and a 200 day simple moving average of $23.78.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. On average, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC boosted its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at about $97,000. BNP Paribas Financial Markets purchased a new position in shares of Enliven Therapeutics during the fourth quarter worth about $112,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics during the fourth quarter worth about $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Enliven Therapeutics in the fourth quarter valued at approximately $228,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ELVN shares. HC Wainwright boosted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.